PubMed Health⌕ Search

PubMed · 15571426

Exercise programmes for patients with chronic heart failure.

Abstract

The safety and efficacy of exercise training in patients with chronic heart failure (CHF) have been reported in a large number of scientific studies, with endurance training representing the most frequently applied training stimulus. Beneath the common continuous method of endurance training, the interval method (short bouts of intense exercise interspersed with pre-scheduled rest intervals), was also applied in some studies. Ergometric testing is a prerequisite for all individualised training prescription and is an appropriate method of efficacy documentation. However, there is a surprisingly large range of exercise intensities being prescribed to patients with CHF. Most of the prescription models refer to maximal ergometric measurements. Submaximal references from lactate and ventilatory curves represent an alternative method in measuring accuracy and efficacy of training. The course of heart rate during submaximal incremental exercise can be reliably used to indicate endurance gains in CHF. Some positive reports exist for carefully executed strength endurance training for patients with CHF and there are convincing arguments for the use of coordination and flexibility exercises; however, substantial scientific evidence is lacking.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Tim Meyer, Michael Kindermann, Wilfried Kindermann. 2004. Exercise programmes for patients with chronic heart failure.. https://doi.org/10.2165/00007256-200434140-00001

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Sleep apnoea and hypertension: role of chemoreflexes in humans.

The link between sleep apnoea and systemic hypertension in humans is well documented. However, a direct causal association between the two diseases independent of comorbidities has been difficult to establish. Comorbidities clearly play an important role in this strong relationship; however, new findings also suggest that sleep apnoea is an independent risk factor for hypertension. This relationship appears to be at least in part a result of chronically elevated sympathetic activity, and therefore manifests as a neurally mediated hypertension. Although the mechanism(s) for this causal relationship of sleep apnoea to hypertension remains ill defined, a growing body of literature suggests that autonomic dysfunction, mediated by abnormal chemoreflex control of sympathetic activity, is a potential mechanism. Abnormal chemoreflex responses to both acute and chronic apnoea or hypoxia have been demonstrated. Hypothesized mechanisms by which chemoreflex dysfunction may contribute to chronically elevated sympathetic tone and ultimately hypertension are explored in this review. Thus, this review focuses on the current evidence linking chemoreflex function to obstructive sleep apnoea and systemic hypertension in humans and provides an analysis of these data and their implications.

Cardiovascular System↗

Gender differences in drug responses.

This review summarizes gender differences (GDs) in drug response. Although GDs have been described both in pharmacodynamics and pharmacokinetics, their role in clinical practice is not yet completely elucidated. The evidence that women have been less enrolled in clinical trials and that a gender-specific analysis usually is not included in the evaluation of results, contributes largely to this uncertainty. Consequently, adverse drug reactions (ADRs) are still higher in females than in males. Since sex is a fundamental biological variable that cannot be discounted, GDs in pharmacology have to be considered in order to improve drug safety efficacy and to optimize medical therapy both in men and women.

Cardiovascular System↗